Opus Genetics, Inc.: Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month data on the first three adult OPGx-LCA5 patients to be pr ...